Lv52
1230 积分 2024-11-12 加入
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
1小时前
已完结
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
13天前
已完结
GLP-1 receptor agonists
13天前
已完结
Dibromocarbene addition to bicyclo[1.1.0]butanes: A facile route to substituted bicyclo[1.1.1]pentanes
20天前
已完结
The expanding landscape of GLP-1 medicines
24天前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
29天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
29天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
29天前
已完结
Oral GLP-1 receptor agonists: competition for efficacy and tolerability
29天前
已关闭
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?
1个月前
已关闭
皖公网安备34019202002308
